FDA orders recommended dosages of sleeping pills to be halved

Share this article:

The Food and Drug Administration is requiring manufacturers of certain sleeping pills, including the widely prescribed Ambien, to reduce current recommended dosages.

Ambien, Ambien CR, Edluar and Zolpimist, as well as the generic forms of Ambien, all contain the ingredient zolpidem, which can cause morning drowsiness. Ambien is considered an effective medication for adults and seniors who can't sleep, although the National Institute of Health cautions that it can cause impaired motor and cognitive function in the elderly. Researchers also found last year that Ambien is among the sleeping pills that increase the risk of hip fracture in nursing home residents.

Studies have shown that women eliminate zolpidem at a slower rate than men, which was part of the logic behind the FDA making manufacturers change the dosage recommendations.

The recommended dosage for women will now be 5 milligrams (down from 10) and 6.25 mg for Ambien CR (down from 12.5 mg). For men, the FDA has said that healthcare professionals should consider prescribing the lower doses as well.

The FDA's change does not affect sleeping aids such as Lunesta and Sonata, which have different ingredients.

The agency encouraged healthcare professionals to use the lowest dose available of a sleeping pill for a patient or resident's insomnia.

Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.